Evaxion Presents New Preclinical Data Supporting EVX-V1 Cytomegalovirus Vaccine Programme
Monday, July 13, 2026
Evaxion A/S has presented new preclinical data supporting its cytomegalovirus (CMV) vaccine programme, EVX-V1, at the International Herpesvirus Workshop (IHW) 2026 in Montreal, Canada.
EVX-V1 is a next-generation, multi-component CMV vaccine candidate developed using the company's AI-Immunology™ platform. The programme combines newly identified B-cell antigens and T-cell epitopes with AI-optimised versions of established structural B-cell antigens to target the virus through multiple immune mechanisms.
The latest findings indicate that AI-discovered T-cell epitopes have the potential to improve control of acute CMV infection, viral latency and reactivation in infected mice. These results complement earlier preclinical studies showing that the novel B-cell antigens reduced viral infection, while the AI-optimised pre-fusion glycoprotein B (gB) antigen achieved stronger virus-neutralising activity than the conventional gB antigen.
According to the company, the new data will help identify the most suitable antigen combination for a broadly protective CMV vaccine candidate. The multi-target approach is also intended to provide a scalable strategy for developing vaccines against other herpesviruses.
CMV remains a significant health concern, particularly for immunocompromised individuals and newborn infants, and there is currently no approved vaccine available.
Evaxion said its AI-Immunology™ platform has identified previously unexplored CMV antigens that trigger targeted immune responses, reduce viral infection and limit cell-to-cell viral spread in laboratory and animal models. EVX-V1 combines these novel antigens with the company's proprietary AI-optimised pre-fusion gB antigen to enhance the vaccine's overall protective potential.
Source: globenewswire.com
